I’m afraid this is a highly technical blog post, but the “take home message” for you should be that having your Advanced PCa genome sequenced for actionable targets (biomarkers) can do much to inform both you and your oncologist on which treatments are likely to benefit you most and which are likely to fail. At the ASCO Conference, Dr. Isla Garraway, David Geffen School of Medicine, UCLA, led a discussion of several of the talks given at the Conference pertaining to predictive biomarkers. Below are a few highlights. For the full summary of her discussion, click here: https://urlzs.com/ZLFxV
- RB1 loss is a poor prognostic sign in mCRPC
- Compound loss of PTEN + RB1 and TP53 + RB1 demonstrates significantly worse outcomes to mCRPC treatments compared to single or no ‘hits’
- HDSB31(1245C) variant consistently demonstrates value as a prognostic/predictive biomarker, showing ADT-resistance and shorter OS in men with low volume mCSPC
- PTEN/TP53 and DNA damage repair alterations are enriched in mCSPC primary tumors